The signal vs substance distinction
Old-school drugs work by being substances. You swallow ibuprofen. The molecule itself blocks an enzyme. The drug is the effect.
Peptides work differently. A peptide doesn't do the work directly - it walks up to a cellular receptor (think: a doorbell on the surface of a cell), rings the bell, and the cell does the work. The peptide itself does almost nothing. The cell does everything.
That's the whole game. Peptides are messages, and your cells already know what to do when they get them.
Why this matters: it means side effects come from the receptor, not the molecule. If a peptide hits the right receptor in the wrong tissue, you get a side effect. If it only hits one receptor, in one tissue, you get a clean response. The point of designing better peptides is making the message more specific.
Why most peptides require an injection
Your stomach is a meat-tenderizer. It evolved to break apart proteins so you can absorb them as amino acids - which means if you swallow a peptide pill, your stomach destroys it before it does anything.
The fix: subcutaneous injection (into the fat layer just under the skin, like an insulin pen). The peptide skips the gut entirely, drips into your bloodstream, and gets distributed.
Same reason insulin isn't a pill. Same reason Ozempic is a pen. The biology is fixed; the delivery mechanism has to work around it.
The exceptions: peptides that survive your stomach
A few peptides are designed (or naturally evolved) to survive stomach acid and stay intact long enough to act locally in the gut.
BPC-157 is the famous example. Your stomach lining makes it for itself - of course it survives stomach acid; that's the whole point. People take it orally for gut-related issues with reasonable evidence behind that route.
Some forms of GHK-Cu work topically. The peptide doesn't have to get into your bloodstream - it can act on the skin directly.
But these are the exceptions. The default assumption: if you read about a peptide, you read about an injectable peptide.
Half-life: why dosing matters
"Half-life" is the time it takes for half of the peptide to clear from your body. This is the dial that determines how often you have to dose.
- Short half-life (minutes to hours): you have to inject multiple times per day. The peptide is gone fast.
- Long half-life (days): you inject once a week. The molecule has been engineered to stick around.
Semaglutide (Ozempic) has a half-life of about 7 days - that's why it's a once-a-week injection. Native GLP-1 (the hormone Ozempic mimics) has a half-life of about 2 minutes. Pharma chemists added a fatty acid tail that lets the molecule bind to a serum protein called albumin, which slows clearance dramatically. Same message. 5,000x longer.
That's not a side issue. That's the breakthrough that made GLP-1 drugs a real product. The peptide message was always known. The problem was getting it to last long enough to dose weekly instead of every two minutes.
Selectivity: the whole point of design
Most peptides hit more than one receptor. Some are very selective; some are messy.
Take GLP-1 vs Tirzepatide. Both are weight-loss peptides.
- Semaglutide (Ozempic / Wegovy) hits one receptor: GLP-1.
- Tirzepatide (Mounjaro / Zepbound) hits two: GLP-1 + GIP. The dual action is why it produces more weight loss in head-to-head trials.
- Retatrutide (in trials) hits three: GLP-1 + GIP + glucagon. Phase 2 data showed even more weight loss. Phase 3 will tell us about long-term safety.
More targets isn't always better. More targets means more potential side effects. The right number depends on what you're trying to accomplish - and that's the design challenge pharma is working on right now.
What this means for normal humans
You don't need to memorize any of this. You need to know three things when you're reading about a peptide:
- What signal does it send? What receptor does it hit, and what does that receptor tell the cell to do? (BPC-157: tissue repair. Semaglutide: appetite + glucose. CJC-1295: growth hormone release.)
- How is it delivered? Injection, oral, topical, intranasal? This determines whether you'll actually take it consistently.
- How specific is it? Hits one receptor or many? More specific generally means cleaner side effects.
Every directory entry on this site answers all three. If your dad asks, you can answer in 30 seconds.
Where to go next
Mechanism context:
- What are peptides - if you skipped the foundation
- The peptide story - 100 years of receptor matchmaking
- What's coming - molecules in late-stage trials
Pick a peptide:
- The Directory - 17 specific peptides reviewed and ranked
- The Tier List - S/A/B/Watch with rationale
Take a protocol:
- The Protocols - 9 step-by-step guides for the protocols people actually run
- Start with BPC-157 - 4-week first protocol for soft-tissue recovery
- GLP-1 Starter - how to start Mounjaro/Wegovy/Zepbound the right way
Subscribe to the dispatch
The weekly Protocol One dispatch covers what's moving in peptides, GLP-1s, and longevity protocols. Free. 5-min read.
Last reviewed · 2026·05·04 · Foundational reference, updated as the field moves